ReviewFuture science OA2025
Emerging threats of monkeypox virus in 2024: current insights and future directions.
Review in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Monkeypox Virus (MPXV) Transmission Dynamics in Neighboring Countries as a Potential Threat to Kazakhstan.Viruses · 2026Review
- Evaluation of a Novel Multiplex PCR Assay for Vesicular Viruses.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monkeypox has reemerged as a major global public health threat, with 2024 witnessing the rise of Clade Ib, a new, more transmissible and potentially severe variant. This review analyzes recent outbreaks, uncovering how Clade Ib has accelerated human-to-human and zoonotic spread, increasing case counts across both endemic and non-endemic regions. The study synthesizes current evidence on the virus's evolving epidemiology, diagnostic advances such as CRISPR and PCR techniques, and progress in vaccine development, focusing on JYNNEOS and ACAM2000. Despite these advancements, significant challenges persist, including timely diagnosis and equitable vaccine access, particularly in low-resource settings. Our findings underscore the importance of sustained genomic surveillance, integrative One Health strategies that unite human, animal, and environmental health data, and robust global collaboration. Addressing these gaps is vital for curbing monkeypox and preparing for future zoonotic threats.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.